http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 01 Nov 2024 14:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html <p>HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. </p> <p>The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity &amp; Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, http://www.streetinsider.com/Press+Releases/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html Fri, 01 Nov 2024 14:00:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html <p>HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. </p> <p>The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity &amp; Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, http://www.streetinsider.com/Press+Releases/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html Fri, 01 Nov 2024 14:00:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html <p>HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. </p> <p>The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity &amp; Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, http://www.streetinsider.com/Press+Releases/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html Fri, 01 Nov 2024 14:00:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html <p>HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. </p> <p>The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity &amp; Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, http://www.streetinsider.com/Globe+Newswire/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html Fri, 01 Nov 2024 14:00:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html <p>HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. </p> <p>The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity &amp; Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, http://www.streetinsider.com/Globe+Newswire/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html Fri, 01 Nov 2024 14:00:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html <p>HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. </p> <p>The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity &amp; Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, http://www.streetinsider.com/Globe+Newswire/Join+Nexalin+Technology%E2%80%99s+Exclusive+Live+Investor+Webinar+and+Q%26amp%3BA+Session+on+November+5th/23915736.html Fri, 01 Nov 2024 14:00:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Corporate+News/Nexalin+Technology+%28NXL%29+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914833.html <p>Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p><p> </p><p>"Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need," said Mark White, CEO of Nexalin. "This achievement not only underscores our commitment to driving shareholder value but also strengthens our visibility among investors as we make strides in http://www.streetinsider.com/Corporate+News/Nexalin+Technology+%28NXL%29+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914833.html Fri, 01 Nov 2024 10:35:21 -0500 NXL NXLIW http://www.streetinsider.com/Corporate+News/Nexalin+Technology+%28NXL%29+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914833.html <p>Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p><p> </p><p>"Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need," said Mark White, CEO of Nexalin. "This achievement not only underscores our commitment to driving shareholder value but also strengthens our visibility among investors as we make strides in http://www.streetinsider.com/Corporate+News/Nexalin+Technology+%28NXL%29+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914833.html Fri, 01 Nov 2024 10:35:21 -0500 NXL NXLIW http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html <p align="justify">HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p> <p>&quot;Regaining compliance with Nasdaq&apos;s listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need,&quot; said Mark White, CEO of Nexalin. &quot;This achievement not only underscores our commitment to http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html Fri, 01 Nov 2024 10:34:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html <p align="justify">HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p> <p>&quot;Regaining compliance with Nasdaq&apos;s listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need,&quot; said Mark White, CEO of Nexalin. &quot;This achievement not only underscores our commitment to http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html Fri, 01 Nov 2024 10:34:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html <p align="justify">HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p> <p>&quot;Regaining compliance with Nasdaq&apos;s listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need,&quot; said Mark White, CEO of Nexalin. &quot;This achievement not only underscores our commitment to http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html Fri, 01 Nov 2024 10:34:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html <p align="justify">HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p> <p>&quot;Regaining compliance with Nasdaq&apos;s listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need,&quot; said Mark White, CEO of Nexalin. &quot;This achievement not only underscores our commitment to http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html Fri, 01 Nov 2024 10:34:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html <p align="justify">HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p> <p>&quot;Regaining compliance with Nasdaq&apos;s listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need,&quot; said Mark White, CEO of Nexalin. &quot;This achievement not only underscores our commitment to http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html Fri, 01 Nov 2024 10:34:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html <p align="justify">HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- <b>Nexalin Technology, Inc. </b>(the “Company” or “Nexalin”) <b>(Nasdaq: NXL; NXLIW) </b>announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).</p> <p>&quot;Regaining compliance with Nasdaq&apos;s listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need,&quot; said Mark White, CEO of Nexalin. &quot;This achievement not only underscores our commitment to http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Regains+Compliance+with+Nasdaq+Continued+Listing+Requirements/23914829.html Fri, 01 Nov 2024 10:34:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html <p align="justify"><b>HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </b>(the “Company” or “Nexalin”) today announced publication of a landmark study titled, “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=L9JZx7gpQN8c-yHnYqqY4Nhp7tjjHzFumgy8iXbpI-MGbTQNEDtw94Vk9vIkasO-5KYU6bHJf96PfFSAGZGdfBr-x1FlVt7LUnzdDIHzT5NnrEvAWu7qixezw0hPByPpupsxiZ_sT9vxKAySi03xmcmC-L5pIjMnIyPhZEraDo5aSUt6RgtqFL2_MfdCQW_RmnQcCO_NXFFw0BPMKRI0iYIX4s-WK3JpgX44zqILjXE5O8HF57PplRnObkyOCKggpOSuLvAHBXamBAsrydvIvbptOJyNGIUyLe1jdX4oGUPM36hXWcb2k9fsM1mhmMxTsOwPrsl3qkCBRgBDWE7PAEfnLZhffO_NQryD8ViYxUo=" rel="nofollow" target="_blank">Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study</a>i” in the Journal of Alzheimer&apos;s Disease. This study builds on recent findings from Nexalin&apos;s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).</p> http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html Mon, 28 Oct 2024 08:30:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html <p align="justify"><b>HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </b>(the “Company” or “Nexalin”) today announced publication of a landmark study titled, “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=L9JZx7gpQN8c-yHnYqqY4Nhp7tjjHzFumgy8iXbpI-MGbTQNEDtw94Vk9vIkasO-5KYU6bHJf96PfFSAGZGdfBr-x1FlVt7LUnzdDIHzT5NnrEvAWu7qixezw0hPByPpupsxiZ_sT9vxKAySi03xmcmC-L5pIjMnIyPhZEraDo5aSUt6RgtqFL2_MfdCQW_RmnQcCO_NXFFw0BPMKRI0iYIX4s-WK3JpgX44zqILjXE5O8HF57PplRnObkyOCKggpOSuLvAHBXamBAsrydvIvbptOJyNGIUyLe1jdX4oGUPM36hXWcb2k9fsM1mhmMxTsOwPrsl3qkCBRgBDWE7PAEfnLZhffO_NQryD8ViYxUo=" rel="nofollow" target="_blank">Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study</a>i” in the Journal of Alzheimer&apos;s Disease. This study builds on recent findings from Nexalin&apos;s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).</p> http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html Mon, 28 Oct 2024 08:30:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html <p align="justify"><b>HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </b>(the “Company” or “Nexalin”) today announced publication of a landmark study titled, “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=L9JZx7gpQN8c-yHnYqqY4Nhp7tjjHzFumgy8iXbpI-MGbTQNEDtw94Vk9vIkasO-5KYU6bHJf96PfFSAGZGdfBr-x1FlVt7LUnzdDIHzT5NnrEvAWu7qixezw0hPByPpupsxiZ_sT9vxKAySi03xmcmC-L5pIjMnIyPhZEraDo5aSUt6RgtqFL2_MfdCQW_RmnQcCO_NXFFw0BPMKRI0iYIX4s-WK3JpgX44zqILjXE5O8HF57PplRnObkyOCKggpOSuLvAHBXamBAsrydvIvbptOJyNGIUyLe1jdX4oGUPM36hXWcb2k9fsM1mhmMxTsOwPrsl3qkCBRgBDWE7PAEfnLZhffO_NQryD8ViYxUo=" rel="nofollow" target="_blank">Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study</a>i” in the Journal of Alzheimer&apos;s Disease. This study builds on recent findings from Nexalin&apos;s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).</p> http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html Mon, 28 Oct 2024 08:30:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html <p align="justify"><b>HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </b>(the “Company” or “Nexalin”) today announced publication of a landmark study titled, “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=L9JZx7gpQN8c-yHnYqqY4Nhp7tjjHzFumgy8iXbpI-MGbTQNEDtw94Vk9vIkasO-5KYU6bHJf96PfFSAGZGdfBr-x1FlVt7LUnzdDIHzT5NnrEvAWu7qixezw0hPByPpupsxiZ_sT9vxKAySi03xmcmC-L5pIjMnIyPhZEraDo5aSUt6RgtqFL2_MfdCQW_RmnQcCO_NXFFw0BPMKRI0iYIX4s-WK3JpgX44zqILjXE5O8HF57PplRnObkyOCKggpOSuLvAHBXamBAsrydvIvbptOJyNGIUyLe1jdX4oGUPM36hXWcb2k9fsM1mhmMxTsOwPrsl3qkCBRgBDWE7PAEfnLZhffO_NQryD8ViYxUo=" rel="nofollow" target="_blank">Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study</a>i” in the Journal of Alzheimer&apos;s Disease. This study builds on recent findings from Nexalin&apos;s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).</p> http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html Mon, 28 Oct 2024 08:30:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html <p align="justify"><b>HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </b>(the “Company” or “Nexalin”) today announced publication of a landmark study titled, “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=L9JZx7gpQN8c-yHnYqqY4Nhp7tjjHzFumgy8iXbpI-MGbTQNEDtw94Vk9vIkasO-5KYU6bHJf96PfFSAGZGdfBr-x1FlVt7LUnzdDIHzT5NnrEvAWu7qixezw0hPByPpupsxiZ_sT9vxKAySi03xmcmC-L5pIjMnIyPhZEraDo5aSUt6RgtqFL2_MfdCQW_RmnQcCO_NXFFw0BPMKRI0iYIX4s-WK3JpgX44zqILjXE5O8HF57PplRnObkyOCKggpOSuLvAHBXamBAsrydvIvbptOJyNGIUyLe1jdX4oGUPM36hXWcb2k9fsM1mhmMxTsOwPrsl3qkCBRgBDWE7PAEfnLZhffO_NQryD8ViYxUo=" rel="nofollow" target="_blank">Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study</a>i” in the Journal of Alzheimer&apos;s Disease. This study builds on recent findings from Nexalin&apos;s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).</p> http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html Mon, 28 Oct 2024 08:30:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html <p align="justify"><b>HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </b>(the “Company” or “Nexalin”) today announced publication of a landmark study titled, “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=L9JZx7gpQN8c-yHnYqqY4Nhp7tjjHzFumgy8iXbpI-MGbTQNEDtw94Vk9vIkasO-5KYU6bHJf96PfFSAGZGdfBr-x1FlVt7LUnzdDIHzT5NnrEvAWu7qixezw0hPByPpupsxiZ_sT9vxKAySi03xmcmC-L5pIjMnIyPhZEraDo5aSUt6RgtqFL2_MfdCQW_RmnQcCO_NXFFw0BPMKRI0iYIX4s-WK3JpgX44zqILjXE5O8HF57PplRnObkyOCKggpOSuLvAHBXamBAsrydvIvbptOJyNGIUyLe1jdX4oGUPM36hXWcb2k9fsM1mhmMxTsOwPrsl3qkCBRgBDWE7PAEfnLZhffO_NQryD8ViYxUo=" rel="nofollow" target="_blank">Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation (tACS): A Resting-State Functional Magnetic Resonance Imaging Study</a>i” in the Journal of Alzheimer&apos;s Disease. This study builds on recent findings from Nexalin&apos;s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).</p> http://www.streetinsider.com/Globe+Newswire/Nexalin+Technology+Announces+Landmark+Study+on+Alzheimer%26apos%3Bs+Disease++and+Deep+Intracranial+Frequency+Stimulation+Published+in+Journal+of+Alzheimer%26apos%3Bs+Disease/23885203.html Mon, 28 Oct 2024 08:30:00 -0500 NXL NXLIW O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html <p align="center"><em>Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model </em></p> <p align="center"><em>Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI)</em></p> <p align="left">HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- <strong>Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </strong>(the “Company” or “Nexalin”) today announced plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD). Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html Tue, 22 Oct 2024 14:15:00 -0500 A.06863842 A.38047855 NXL NXLIW O.22632256 O.23919976 O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html <p align="center"><em>Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model </em></p> <p align="center"><em>Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI)</em></p> <p align="left">HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- <strong>Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </strong>(the “Company” or “Nexalin”) today announced plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD). Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html Tue, 22 Oct 2024 14:15:00 -0500 A.06863842 A.38047855 NXL NXLIW O.22632256 O.23919976 O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html <p align="center"><em>Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model </em></p> <p align="center"><em>Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI)</em></p> <p align="left">HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- <strong>Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </strong>(the “Company” or “Nexalin”) today announced plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD). Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html Tue, 22 Oct 2024 14:15:00 -0500 A.06863842 A.38047855 NXL NXLIW O.22632256 O.23919976 O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html <p align="center"><em>Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model </em></p> <p align="center"><em>Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI)</em></p> <p align="left">HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- <strong>Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </strong>(the “Company” or “Nexalin”) today announced plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD). Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html Tue, 22 Oct 2024 14:15:00 -0500 A.06863842 A.38047855 NXL NXLIW O.22632256 O.23919976 O.41318195 http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html <p align="center"><em>Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model </em></p> <p align="center"><em>Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild Traumatic Brain Injury (mTBI)</em></p> <p align="left">HOUSTON, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- <strong>Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) </strong>(the “Company” or “Nexalin”) today announced plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD). Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation http://www.streetinsider.com/Press+Releases/Nexalin+Technology+Announces+Planned+Clinical+Trial+Utilizing+Gen-3+Halo+Headset+in+Partnership+with+UC+San+Diego+%26amp%3B+San+Diego+VA/23864216.html Tue, 22 Oct 2024 14:15:00 -0500 A.06863842 A.38047855 NXL NXLIW O.22632256 O.23919976 O.41318195